Catalog No.
RHE46003
Species reactivity
Human
Host species
Mouse
Isotype
IgG1
Clonality
Monoclonal
Tested applications
ELISA: 1:10000, FCM: 1:200-1:400, IHC: 1:200-1:1000, WB: 1:500-1:2000
Target
MEK 4, MEK4, SAPK kinase 1, JNKK, c-Jun N-terminal kinase kinase 1, SEK1, JNK-activating kinase 1, MAPK/ERK kinase 4, MAPKK 4, SERK1, SKK1, SAPKK-1, SAPK/ERK kinase 1, PRKMK4, MKK4, MAP kinase kinase 4, MAP2K4, Dual specificity mitogen-activated protein kinase kinase 4, SAPKK1, Stress-activated protein kinase kinase 1, JNKK1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P45985
Applications
ELISA, FCM, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R3L42
Tissue-origin transcriptomic interactions as indicators of inflammatory aging and aging gene discovery., PMID:40527241
E203K mutation in MAP2K1 (MEK1) causes acquired resistance to PD-1 blockade but responds to trametinib: a case report., PMID:39806853
First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis., PMID:33495600
MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway., PMID:33436306
Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma., PMID:33043759
Immunoglobulin deficiency associated with a MAP2K1-related mutation causing cardio-facio-cutaneous syndrome., PMID:32866538
Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer., PMID:32805066
BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer., PMID:32047001
Genomic and immune profiling of pre-invasive lung adenocarcinoma., PMID:31784532
V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer., PMID:31227518
Pediatric Langerhans cell histiocytosis: the impact of mutational profile on clinical progression and late sequelae., PMID:30923995
CRISPR/Cas9-Mediated Knockout of MicroRNA-744 Improves Antibody Titer of CHO Production Cell Lines., PMID:30802343
Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8+ T-cells infiltration in triple-negative breast cancer., PMID:30777101
Phorbol esters induce PLVAP expression via VEGF and additional secreted molecules in MEK1-dependent and p38, JNK and PI3K/Akt-independent manner., PMID:30394679
Anti-β2 -glycoprotein I antibody with DNA binding activity enters living monocytes via cell surface DNA and induces tissue factor expression., PMID:30368780
Alterations of MEK1/2-ERK1/2, IFNγ and Smad2/3 associated Signalling pathways during cryopreservation of ASCs affect their differentiation towards VSMC-like cells., PMID:30273905
Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand., PMID:30250119
The effect of human herpesvirus 6B infection on the MAPK pathway., PMID:30130603
ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma., PMID:30115691
Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse?, PMID:29851931
MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment., PMID:29767411
Acetylation regulates the MKK4-JNK pathway in T cell receptor signaling., PMID:29248490
Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations., PMID:29107340
Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia., PMID:28918710
MKK4 activates non-canonical NFκB signaling by promoting NFκB2-p100 processing., PMID:28733031
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS., PMID:28592615
Interaction of molecular alterations with immune response in melanoma., PMID:28543700
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma., PMID:28543695
Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies., PMID:28236768
Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer., PMID:27636997
Gene signatures related to HAI response following influenza A/H1N1 vaccine in older individuals., PMID:27441275
Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment., PMID:27341591
A Phos-tag SDS-PAGE method that effectively uses phosphoproteomic data for profiling the phosphorylation dynamics of MEK1., PMID:27169363
Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer., PMID:26644315
Hairy cell leukaemia-variant: Disease features and treatment., PMID:26614904
The genomic landscape of response to EGFR blockade in colorectal cancer., PMID:26416732
Targeted inhibition of MEK1 by cobimetinib leads to differentiation and apoptosis in neuroblastoma cells., PMID:26384788
Amphiregulin enhances alpha6beta1 integrin expression and cell motility in human chondrosarcoma cells through Ras/Raf/MEK/ERK/AP-1 pathway., PMID:25825984
Interleukin-1 Acts via the JNK-2 Signaling Pathway to Induce Aggrecan Degradation by Human Chondrocytes., PMID:25776267
Brominated flame retardants, tetrabromobisphenol A and hexabromocyclododecane, activate mitogen-activated protein kinases (MAPKs) in human natural killer cells., PMID:25341744
Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9., PMID:25326806
Regulation of the mitogen-activated protein kinase kinase (MEK)-1 by NAD(+)-dependent deacetylases., PMID:24681949
The FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth and survival., PMID:24445144
High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias., PMID:24241536
Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines., PMID:24192080
Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients., PMID:24170544
New targets and new mechanisms in lung cancer., PMID:25184262
Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin., PMID:22242821
Stress-activated kinase pathway alteration is a frequent event in bladder cancer., PMID:22154358
Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells., PMID:22086413
For research use only. Not for human or drug use.
